Enzymotec launches product for diabetes patients

Diabetes is a multiple metabolic disorder, characterized also by abnormal fat metabolism. Recent clinical evidence shows that the rates of heart disease deaths in diabetes patients are about 2 to 4 times higher than in adults without diabetes. Moreover, about 85 per cent of deaths among people with diabetes are due to heart diseases and strokes. Therefore, diabetes patients are obliged to get better heart health solutions in order to avoid these risks.

Enzymotec recently demonstrated in an animal study that its functional oil formulation, MultOil, may reduce the risk for coronary heart disease through a triple action on heart health : it prevents and controls oxidative stress, reduces total cholesterol and triglyceride levels and inhibits the atherosclerotic plaque formation cascade.

Last month it used this data to back the launch of a heart health product ArteriCare​. It has now branded a new line, under the carDiabeat name, specifically for diabetics.

"The accepted approach for diabetics' nutrition is always based on low-carb diets, while totally ignoring the heart health complications associated with diabetes,"​ said Dr Ariel Katz, Enzymotec's CEO. "Our ground breaking approach is to tackle diabetics' heart health risks by providing a nutritional solution designed especially to meet their unique health needs and protects them from the serious implications of abnormal fat metabolism."​

carDiabeat can be used in capsules, tablets, or liquid applications, as well as nutrition bars or in functional foods such as dairy products, salad dressings and bakery products.